Kong Yali, Grembecka Jolanta, Edler Michael C, Hamel Ernest, Mooberry Susan L, Sabat Michal, Rieger Jayson, Brown Milton L
Department of Chemistry, University of Virginia, Charlottesville, 22904, USA.
Chem Biol. 2005 Sep;12(9):1007-14. doi: 10.1016/j.chembiol.2005.06.016.
Targeting the microtubule system represents an attractive strategy for the development of anticancer agents. In this study, we report a class of combretastatin A-4 (CA-4) analogs derivatized with a boronic acid moiety replacing the hydroxyl group on the C-ring of CA-4. Docking studies of the X-ray structures of our aryl-boronic analogs onto an X-ray structure of the alpha,beta-tubulin heterodimer suggested that cis-6 was a potent inhibitor of the colchicine binding. The model indicated that there would be strong hydrogen bonding between the boronic acid moiety and Thr-179 and Val-181 of alpha-tubulin. We demonstrate that the cis-6 boronic acid bioisostere of CA-4: (1) inhibits tubulin assembly, (2) competitively displaces colchicine, and (3) is a low-nanomolar inhibitor of human cancer cell lines. We present this isostere as a class of potent analogs of CA-4.
靶向微管系统是开发抗癌药物的一种有吸引力的策略。在本研究中,我们报道了一类柯里拉京A-4(CA-4)类似物,其通过硼酸部分衍生化,取代了CA-4 C环上的羟基。将我们的芳基硼酸类似物的X射线结构对接至α,β-微管蛋白异二聚体的X射线结构上的研究表明,顺式-6是秋水仙碱结合的有效抑制剂。该模型表明硼酸部分与α-微管蛋白的Thr-179和Val-181之间会形成强氢键。我们证明CA-4的顺式-6硼酸生物电子等排体:(1)抑制微管蛋白组装,(2)竞争性取代秋水仙碱,(3)是人类癌细胞系的低纳摩尔抑制剂。我们将这种生物电子等排体作为一类有效的CA-4类似物呈现。